title: Picotamide inhibition of excess in vitro thromboxane B2 release by colorectal mucosa in inflammatory bowel disease.
abstract: BACKGROUND
  Inflammatory bowel disease is associated with increased mucosal release of eicosanoids. Among these, thromboxane A2 has been proposed as a possible inflammatory mediator; its suppression may be a useful therapeutic option.
  
  
  METHODS
  Using a tissue incubation technique, we compared release of immunoreactive thromboxane B2 by colonic biopsies from patients with ulcerative colitis, Crohn's disease and controls, and assessed the inhibitory effect of picotamide, a thromboxane synthesis inhibitor-receptor antagonist, which has been widely used in Italy for management of ischaemic heart and cerebrovascular disease.
  
  
  RESULTS
  Increased amounts of thromboxane B2 were released from biopsies from patients with active ulcerative colitis (median 238 pg/20 min/mg wet weight (interquartile range 147-325), n = 12) and active Crohn's disease (252 (174-450), 6) compared with those from patients with quiescent ulcerative colitis (95 (61-140), 12) or Crohn's disease (105 (57-201), 13), or controls (136 (64-206), 8). Incubation with picotamide at concentrations between 100 microM and 1 mM reduced thromboxane B2 release (IC50 890 microM).
  
  
  CONCLUSIONS
  Since increased thromboxane A2 production may have pathogenetic importance, thromboxane synthesis inhibitor-receptor antagonists such as picotamide merit therapeutic trial in the management of inflammatory bowel disease.
authors.affiliation: Gastrointestinal Science Research Unit, London Hospital Medical College, UK.
authors.forename: C E
authors.initials: CE
authors.lastname: Collins
authors.forename: M J
authors.initials: MJ
authors.lastname: Benson
authors.forename: W R
authors.initials: WR
authors.lastname: Burnham
authors.forename: D S
authors.initials: DS
authors.lastname: Rampton
mesh_terms: D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D003093:Colitis, Ulcerative / Q000378:metabolism; D003106:Colon / Q000187:drug effects / Q000378:metabolism; D003424:Crohn Disease / Q000378:metabolism; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D015212:Inflammatory Bowel Diseases / Q000378:metabolism*; D007413:Intestinal Mucosa / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D010795:Phthalic Acids / Q000494:pharmacology*; D012007:Rectum / Q000187:drug effects / Q000378:metabolism; D013929:Thromboxane B2 / Q000378:metabolism*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D010795:Phthalic Acids; D013929:Thromboxane B2; C011581:picotamide